{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T02:12:07Z","timestamp":1787883127296,"version":"build-2784847793"},"reference-count":46,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"vor","delay-in-days":1461,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1038\/ki.2012.327","type":"journal-article","created":{"date-parts":[[2012,9,5]],"date-time":"2012-09-05T11:20:26Z","timestamp":1346844026000},"page":"160-166","source":"Crossref","is-referenced-by-count":132,"title":["Higher fibroblast growth factor-23 increases the risk of all-cause and cardiovascular mortality in the community"],"prefix":"10.1016","volume":"83","author":[{"given":"Johan","family":"\u00c4rnl\u00f6v","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel C.","family":"Carlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Sundstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Ingelsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Larsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Lind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias E.","family":"Larsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/ki.2012.327_bb0010","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrneph.2011.53","article-title":"Mineral metabolism and vitamin D in chronic kidney disease--more questions than answers","volume":"7","author":"Goldsmith","year":"2011","journal-title":"Nat Rev Nephrol"},{"key":"10.1038\/ki.2012.327_bb0015","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1681\/ASN.2004040275","article-title":"Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study","volume":"16","author":"Slinin","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2012.327_bb0020","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1161\/ATVBAHA.109.196675","article-title":"Conjoint effects of serum calcium and phosphate on risk of total, cardiovascular, and noncardiovascular mortality in the community","volume":"30","author":"Larsson","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1038\/ki.2012.327_bb0025","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1161\/CIRCULATIONAHA.108.808733","article-title":"Plasma parathyroid hormone and the risk of cardiovascular mortality in the community","volume":"119","author":"Hagstrom","year":"2009","journal-title":"Circulation"},{"key":"10.1038\/ki.2012.327_bb0030","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1001\/archinte.167.9.879","article-title":"Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community","volume":"167","author":"Dhingra","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1038\/ki.2012.327_bb0035","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/81664","article-title":"Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23","volume":"26","author":"ADHR Consortium","year":"2000","journal-title":"Nat Genet"},{"key":"10.1038\/ki.2012.327_bb0040","first-page":"4003","article-title":"The parathyroid is a target organ for FGF23 in rats","volume":"117","author":"Ben-Dov","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1038\/ki.2012.327_bb0045","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1677\/JOE-07-0267","article-title":"Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells","volume":"195","author":"Krajisnik","year":"2007","journal-title":"J Endocrinol"},{"key":"10.1038\/ki.2012.327_bb0050","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1359\/JBMR.0301264","article-title":"FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis","volume":"19","author":"Shimada","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1038\/ki.2012.327_bb0055","doi-asserted-by":"crossref","first-page":"6500","DOI":"10.1073\/pnas.101545198","article-title":"Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia","volume":"98","author":"Shimada","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/ki.2012.327_bb0060","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1161\/CIRCULATIONAHA.111.053405","article-title":"Vascular klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23","volume":"125","author":"Lim","year":"2012","journal-title":"Circulation"},{"key":"10.1038\/ki.2012.327_bb0065","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1172\/JCI46122","article-title":"FGF23 induces left ventricular hypertrophy","volume":"121","author":"Faul","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1038\/ki.2012.327_bb0070","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1046\/j.1523-1755.2003.00328.x","article-title":"Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers","volume":"64","author":"Larsson","year":"2003","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2012.327_bb0075","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1681\/ASN.2006080936","article-title":"Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study","volume":"18","author":"Fliser","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2012.327_bb0080","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMoa0706130","article-title":"Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis","volume":"359","author":"Gutierrez","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2012.327_bb0085","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1001\/jama.2011.826","article-title":"Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease","volume":"305","author":"Isakova","year":"2011","journal-title":"JAMA"},{"key":"10.1038\/ki.2012.327_bb0090","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1093\/ndt\/gfp191","article-title":"High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients","volume":"24","author":"Jean","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/ki.2012.327_bb0095","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1681\/ASN.2010121224","article-title":"FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis","volume":"22","author":"Kendrick","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2012.327_bb0100","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1681\/ASN.2010080894","article-title":"Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality","volume":"22","author":"Wolf","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2012.327_bb0105","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1681\/ASN.2010121224","article-title":"FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis","volume":"22","author":"Kendrick","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2012.327_bb0110","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1093\/ndt\/gfq309","article-title":"FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment","volume":"25","author":"Seiler","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/ki.2012.327_bb0115","doi-asserted-by":"crossref","first-page":"640","DOI":"10.7326\/0003-4819-152-10-201005180-00004","article-title":"The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study","volume":"152","author":"Parker","year":"2010","journal-title":"Ann Intern Med"},{"key":"10.1038\/ki.2012.327_bb0120","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1681\/ASN.2005010052","article-title":"Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease","volume":"16","author":"Gutierrez","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2012.327_bb0125","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s00223-011-9501-5","article-title":"Fibroblast growth factor 23 (FGF23) and alpha-klotho stimulate osteoblastic MC3T3.E1 cell proliferation and inhibit mineralization","volume":"89","author":"Shalhoub","year":"2011","journal-title":"Calcif Tissue Int"},{"key":"10.1038\/ki.2012.327_bb0130","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1359\/jbmr.080220","article-title":"Overexpression of fibroblast growth factor 23 suppresses osteoblast differentiation and matrix mineralization in vitro","volume":"23","author":"Wang","year":"2008","journal-title":"J Bone Miner Res"},{"key":"10.1038\/ki.2012.327_bb0135","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.atherosclerosis.2009.01.001","article-title":"Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community","volume":"205","author":"Mirza","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1038\/ki.2012.327_bb0140","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/ki.2010.194","article-title":"FGF-23 and vascular dysfunction in patients with stage 3 and 4 chronic kidney disease","volume":"78","author":"Yilmaz","year":"2010","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2012.327_bb0145","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1093\/ndt\/gfn571","article-title":"Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences","volume":"24","author":"Jean","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/ki.2012.327_bb0150","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1093\/ndt\/gfp205","article-title":"Relationship between circulating FGF23 and total body atherosclerosis in the community","volume":"24","author":"Mirza","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/ki.2012.327_bb0155","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1093\/ndt\/gfq089","article-title":"Fibroblast growth factor-23 (FGF-23) is independently correlated to aortic calcification in haemodialysis patients","volume":"25","author":"Nasrallah","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/ki.2012.327_bb0160","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1172\/JCI46122","article-title":"FGF23 induces left ventricular hypertrophy","volume":"121","author":"Faul","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1038\/ki.2012.327_bb0165","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1161\/CIRCULATIONAHA.108.844506","article-title":"Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease","volume":"119","author":"Gutierrez","year":"2009","journal-title":"Circulation"},{"key":"10.1038\/ki.2012.327_bb0170","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.atherosclerosis.2009.05.013","article-title":"Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population","volume":"207","author":"Mirza","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1038\/ki.2012.327_bb0175","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1093\/ndt\/gfr144","article-title":"Lanthanum carbonate reduces FGF23 in chronic kidney disease stage 3 patients","volume":"26","author":"Gonzalez-Parra","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/ki.2012.327_bb0180","doi-asserted-by":"crossref","first-page":"286","DOI":"10.2215\/CJN.05420709","article-title":"Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?","volume":"5","author":"Oliveira","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1038\/ki.2012.327_bb0185","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1161\/01.CIR.90.1.583","article-title":"Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents","volume":"90","author":"Tunstall-Pedoe","year":"1994","journal-title":"Circulation"},{"key":"10.1038\/ki.2012.327_bb0190","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1097\/HJH.0b013e328122dd58","article-title":"Diabetes in treated hypertension is common and carries a high cardiovascular risk: results from a 28-year follow-up","volume":"25","author":"Almgren","year":"2007","journal-title":"J Hypertens"},{"key":"10.1038\/ki.2012.327_bb0195","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1681\/ASN.2008121258","article-title":"Indirect regulation of PTH by estrogens may require FGF23","volume":"20","author":"Carrillo-Lopez","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2012.327_bb0200","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/ki.2010.161","article-title":"Associations of estradiol and testosterone with serum phosphorus in older men: the Osteoporotic Fractures in Men study","volume":"78","author":"Meng","year":"2010","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2012.327_bb0205","doi-asserted-by":"crossref","first-page":"F882","DOI":"10.1152\/ajprenal.00360.2010","article-title":"PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop","volume":"299","author":"Lavi-Moshayoff","year":"2010","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1038\/ki.2012.327_bb0210","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/BF02563790","article-title":"Adrenal responses to subtotal parathyroidectomy for primary hyperparathyroidism","volume":"41","author":"Pacifici","year":"1987","journal-title":"Calcif Tissue Int"},{"key":"10.1038\/ki.2012.327_bb0215","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1161\/01.CIR.0000124718.99562.91","article-title":"Association of type 2 diabetes with cyclooxygenase-mediated inflammation and oxidative stress in an elderly population","volume":"109","author":"Helmersson","year":"2004","journal-title":"Circulation"},{"key":"10.1038\/ki.2012.327_bb0220","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1017\/S0007114508147377","article-title":"Low dietary intake of beta-carotene, alpha-tocopherol and ascorbic acid is associated with increased inflammatory and oxidative stress status in a Swedish cohort","volume":"101","author":"Helmersson","year":"2009","journal-title":"Br J Nutr"},{"key":"10.1038\/ki.2012.327_bb0225","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1080\/00365510601187773","article-title":"Evaluation of gentian cystatin C reagent on Abbott Ci8200 and calculation of glomerular filtration rate expressed in ml\/min\/1.73 m(2) from the cystatin C values in mg\/l","volume":"67","author":"Flodin","year":"2007","journal-title":"Scand J Clin Lab Invest"},{"key":"10.1038\/ki.2012.327_bb0230","series-title":"The Minnesota Code Manual of Electrocardiographic Findings: Standards and Procedures for Measurement and Classification","author":"Prineas","year":"1982"},{"key":"10.1038\/ki.2012.327_bb0235","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/jama.1996.03530440037034","article-title":"The progression from hypertension to congestive heart failure","volume":"275","author":"Levy","year":"1996","journal-title":"JAMA"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815556986?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815556986?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,3]],"date-time":"2019-07-03T08:52:17Z","timestamp":1562143937000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253815556986"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["S0085253815556986"],"URL":"https:\/\/doi.org\/10.1038\/ki.2012.327","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717978132.793470994","asserted-by":"object"}]},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]}}}